Mai H Barnard, in Garden Grove, CA - Behavior Technician

Mai H Barnard, is a Behavior Technician based in Garden Grove, California. Mai H Barnard is licensed to practice in * (Not Available) (license number ) and her current practice location is 12792 Valley View St Ste 205, Garden Grove, California. She can be reached at her office (for appointments etc.) via phone at (714) 337-6484.

NPI number for Mai H Barnard is 1114226305 and her current mailing address is 12792 Valley View St Ste 205, Garden Grove, California. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1114226305.

Contact Information

	Mai H Barnard,
	12792 Valley View St Ste 205, Garden Grove, CA 92845-2510
	(714) 337-6484
	Not Available

Healthcare Provider's Profile

Full Name	Mai H Barnard
Gender	Female
Speciality	Behavior Technician
Location	12792 Valley View St Ste 205, Garden Grove, California
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1114226305
Provider Enumeration Date: 03/28/2011
Last Update Date: 12/16/2019

Medical Identifiers

Medical identifiers for Mai H Barnard such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1114226305	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
225X00000X	Occupational Therapist	511 (Colorado)	Secondary
106S00000X	Behavior Technician	(* (Not Available))	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Mai H Barnard is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Mai H Barnard, 12792 Valley View St Ste 205, Garden Grove, CA 92845-2510 Ph: (714) 337-6484	Mai H Barnard, 12792 Valley View St Ste 205, Garden Grove, CA 92845-2510 Ph: (714) 337-6484

News Archive

Keryx completes randomization of last patient in Zerenex Phase 3 study for hyperphosphatemia

Keryx Biopharmaceuticals reported today the randomization of the last patient in its short-term study component of its Phase 3 registration program of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.

Study analyzes quality of protein supplements in function of source, treatment and storage

Powdered protein supplements are one of the most commonly consumed nutritional supplements, whether by professional sportspeople or amateurs, even by those who use them for aesthetic purposes instead of sporting ones.

Moderate alcohol consumption linked with lower risk of hospitalization

A study of the Department of Epidemiology and Prevention of I.R.C.C.S. Neuromed, in collaboration with the Department of Nutrition of the Harvard T.H. Chan School of Public Health, highlights that people who consume alcohol moderately (one glass of wine a day), in the general framework of Mediterranean diet principles, have a lower risk of being hospitalized compared to heavier drinkers, but also to the teetotallers.

People over 70 can safely donate a kidney without risking their lives

People over age 70 years of age can safely donate a kidney, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). The results provide good news for patients who need a kidney but have limited options for donors; however, kidneys from these elderly donors do not last as long as those from younger living donors.

Janssen, Medivir and Idenix partner for clinical development of HCV combination therapy

Medivir AB today announced a non-exclusive collaboration between Janssen Pharmaceuticals Inc. (Janssen) and Idenix Pharmaceuticals for the clinical development of an all-oral (interferon-free) direct-acting antiviral (DAA) hepatitis C (HCV) combination therapy.

Mai H Barnard, - in Garden Grove, CA